Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05260671 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 18, 2023 (before its estimated December 25, 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 25, 2024 to Dec 25, 2024
    • Study completion date: Dec 25, 2025 to Dec 25, 2026
    • Eligibility criteria expanded, about 2 words
    v4
  2. Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 1 to 2
    v3
  3. Eligibility criteria shortened, about 18 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Trial Details
NCT Number NCT05260671
Lead Sponsor Eye & ENT Hospital of Fudan University
Conditions
(from sponsor)		 Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
Related terms Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov